Search Results - "de Azambuja E"

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

Authors: Tolaney, S. M. de Azambuja, E. Kalinsky, K. et al.

Source: New England Journal of Medicine. 1/22/2026, Vol. 394 Issue 4, p354-366. 13p.

20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment.

Authors: Gentile, G. Gerosa, R. de Azambuja, E. et al.

Source: Annals of Oncology. Apr2026, Vol. 37 Issue 4, p470-480. 11p.

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients.

Authors: de Azambuja, E. Cardoso, F. de Castro, G. et al.

Source: British Journal of Cancer. 5/21/2007, Vol. 96 Issue 10, p1504-1513. 10p. 1 Diagram, 4 Charts.

276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

Authors: Tolaney, S.M. de Azambuja, E. Emens, L.A. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS664-S665. 2p.

The landscape of medical oncology in Europe by 2020†.

Authors: de Azambuja, E. Ameye, L. Paesmans, M. et al.

Source: Annals of Oncology. Feb2014, Vol. 25 Issue 2, p525-528. 4p. 3 Charts, 2 Graphs.

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors: de Azambuja, E. Zardavas, D. Lemort, M. et al.

Source: Annals of Oncology. Dec2013, Vol. 24 Issue 12, p2985-2989. 5p.

Improving quality of life after breast cancer: Dealing with symptoms.

Authors: Pinto AC de Azambuja E

Source: Maturitas. Dec2011, Vol. 70 Issue 4, p343-348. 6p.

Long-term toxic effects of adjuvant chemotherapy in breast cancer.

Authors: Azim, H. A. de Azambuja, E. Colozza, M. et al.

Source: Annals of Oncology. Sep2011, Vol. 22 Issue 9, p1939-1947. 9p. 3 Charts.

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Authors: Saini, K.S. Koopman, M. Martins-Branco, D. et al.

Source: Annals of Oncology. May2026, Vol. 37 Issue 5, p608-623. 16p.

159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts).

Authors: Eiger, D. de Azambuja, E. Moreau, M. et al.

Source: Annals of Oncology. 2020 Supplement 2, Vol. 31, pS73-S74. 2p. 1 Chart.

553P Impact of trop-2 expression on the efficacy of TROP-2–targeted antibody–drug conjugates in patients with metastatic breast cancer: A systematic review and meta-analysis.

Authors: Buonaiuto, R. Pagliuca, M. De Azambuja, E. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS436-S437. 2p.

Tumour heterogeneity in molecular imaging for breast cancer.

Authors: Lobo-Martins, S. Agostinetto, E. de Azambuja, E. et al.

Source: Annals of Oncology. Nov2024, Vol. 35 Issue 11, p1061-1062. 2p.

Molecular profiling of a tumor of unknown origin.

Authors: Ismael G de Azambuja E Awada A

Source: New England Journal of Medicine. 9/7/2006, Vol. 355 Issue 10, p1071-1072. 2p.

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC).

Authors: Fernandez-Martinez, A. Tanioka, M. Ahn, S.G. et al.

Source: Annals of Oncology. Apr2025, Vol. 36 Issue 4, p403-413. 11p.

Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients.

Authors: Fouad, T. M. de Azambuja, E. Azim Jr., H. A.

Source: Annals of Oncology. Jul2015, Vol. 26 Issue 7, p1511-1511. 2/3p.

236 (PB-060) Poster - Circulating microRNAs for early detection of therapy-related cardiac events in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO.

Authors: Pizzamiglio, S. Ciniselli, C.M. De Azambuja, E. et al.

Source: European Journal of Cancer. 2022 Supplement 1, Vol. 175, pS77-S78. 2p.

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Authors: Ades, F. Senterre, C. de Azambuja, E. et al.

Source: Annals of Oncology. Nov2013, Vol. 24 Issue 11, p2897-2902. 6p. 3 Charts, 3 Graphs.

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors: Capelan, M. Pugliano, L. De Azambuja, E. et al.

Source: Annals of Oncology. Feb2013, Vol. 24 Issue 2, p273-282. 10p. 2 Diagrams, 4 Charts.

685P Systemic efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with central nervous system (CNS) metastases (mets) from solid tumors: A systematic review and meta-analysis.

Authors: Lobo-Martins, S. Martins-Branco, D. Lara, C. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS492-S493. 2p.

666MO Reliability of cerebrospinal fluid (CSF) ctDNA as a surrogate for tumor mutational profiling in central nervous system (CNS) metastases: Results from the BrainStorm (OncoDistinct006) study.

Authors: Arecco, L. Rothé, F. Venet, D. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS485-S486. 2p.